Lyka Labs
69.06
-1.15(-1.64%)
Market Cap₹246.48 Cr
PE Ratio-707.10
IndustryHealthcare
Company Performance:
1D-1.64%
1M-11.50%
6M-32.82%
1Y-43.83%
5Y+122.77%
View Company Insightsright
More news about Lyka Labs
24Sept 25
Lyka Labs to Consider Preference Share Redemption and Company Secretary Appointment in Upcoming Board Meeting
Lyka Labs Limited has scheduled a board meeting for September 29, 2025, to discuss important corporate matters. The agenda includes considering the redemption of 1,08,570 unlisted 10% Cumulative Redeemable Preference Shares valued at Rs.100 each, totaling approximately Rs.1.09 crore. The board will also deliberate on appointing a Company Secretary and Compliance Officer. Additional business matters will be addressed, though details are not specified. The company has informed both BSE and NSE about the meeting in compliance with SEBI regulations.
 no imag found
18Sept 25
Lyka Labs' Amalgamation with Lyka Exports Faces Delay as NCLT Seeks Income Tax Report
Lyka Labs Limited reported a slight delay in its amalgamation process with Lyka Exports Limited. The National Company Law Tribunal (NCLT), Ahmedabad Bench, has requested the Income Tax Department to submit a report within seven days regarding the joint petition. The NCLT will further consider the case on October 9. This development follows the NCLT's previous indication of 'no objection' to the amalgamation scheme.
 no imag found
08Aug 25
NCLT Reserves Order on Lyka Labs-Lyka Exports Merger, Signals No Objection
The National Company Law Tribunal (NCLT) Ahmedabad Bench has reserved its order on the proposed merger between Lyka Labs Limited and Lyka Exports Limited. During the hearing on August 7, 2025, the NCLT indicated 'no objection' to the scheme of amalgamation. Lyka Labs, the transferee company, awaits formal pronouncement of the order. The company's Managing Director & CEO, Kunal Gandhi, stated that necessary disclosures will be made once the NCLT order is formally pronounced.
 no imag found
01Aug 25
Lyka Labs Announces Q1 Results, Management Changes, and New Internal Auditor Appointment
Lyka Labs Limited has approved unaudited financial results for Q1 FY2025-26. The company secretary, Mr. Shekhar R Singh, has resigned effective August 1, 2025. Sudit K Parekh & Co. LLP has been appointed as the new internal auditor for FY2025-26, effective August 1, 2025.
 no imag found
01Aug 25
Lyka Labs Approves Q1 Results, Announces Key Management Changes
Lyka Labs Limited has approved its unaudited financial results for Q1 FY2025-26. The company's Company Secretary, Mr. Shekhar R Singh, has resigned effective August 1, 2025. Sudit K Parekh & Co. LLP has been appointed as the Internal Auditor for FY2025-26. These decisions were made during a Board meeting held on August 1, 2025.
 no imag found
26May 25
Lyka Labs Reports Improved Q4 EBITDA and Margin, Swings to Profit as Revenue Surges
Lyka Labs reported a net profit of ₹18 million in Q4, reversing a ₹21 million loss from the previous year. Revenue grew by 20% year-over-year to ₹334 million. EBITDA increased to ₹41 million from ₹20 million, with the EBITDA margin improving to 12.23% from 7.31%. Despite a slight decrease from Q3's profit of ₹27 million, the company maintains profitability.
 no imag found
08Apr 25
Lyka Labs Secures Indian Patent for Innovative Pregabalin Gel 8%
Lyka Labs Limited has been granted a patent by the Patent Office India for Pregabalin Gel 8%, a novel topical solution for managing diabetic neuropathic pain. The patent extends protection until 2043. The product, first of its kind in India, received CDSCO approval in October 2024 and was launched in December 2024. Lyka Labs has partnered with Torrent Pharmaceuticals, Intas Pharmaceuticals, and Zuventus Healthcare for manufacturing and marketing the gel through P2P licenses.
 no imag found
Lyka Labs
69.06
-1.15
(-1.64%)
1 Year Returns:-43.83%
Industry Peers
Sun Pharmaceutical
1,697.50
(-1.01%)
Divis Laboratories
6,168.50
(-0.27%)
Torrent Pharmaceuticals
4,078.00
(+0.02%)
Cipla
1,331.50
(+0.11%)
Dr Reddys Laboratories
1,268.10
(-0.53%)
Lupin
2,199.30
(-0.53%)
Zydus Life Science
904.70
(-1.76%)
Mankind Pharma
2,060.50
(-0.89%)
Aurobindo Pharma
1,145.60
(-1.06%)
Alkem Laboratories
5,402.50
(-7.97%)